TITLE

RESEARCH & TECHNOLOGY

PUB. DATE
August 2010
SOURCE
MondayMorning;8/2/2010, Vol. 18 Issue 29, p4
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
The article presents news brief related to the drug industry. Allos Therapeutics Inc. reports that its lung-cancer drug Folotyn increased survival of patients, however, the lower sales raised concern about the marketing opportunity. A study revealed that prostate cancer vaccine Provenge developed by Dendreon Crop. extends lives by about 4 months. Onyx Pharmaceuticals Inc. reported a positive clinical trial result of its cancer drug Carfilzomib.
ACCESSION #
52731370

 

Related Articles

  • WEEK IN REVIEW.  // BioWorld Insight;10/19/2009, Vol. 17 Issue 42, p6 

    The article presents financings and deals of pharmaceutical companies. Adventrx Pharmaceuticals Inc. received a gross income of 11.3 million dollars from its registered direct offering of stock and warrants. Allos Therapeutics Inc. obtained on its disclosed public stock offering a net income of...

  • New drug demonstrates favorable toxicity profile and efficacy in previously treated non-small cell lung cancer patients.  // PharmaWatch: Cancer;August 2003, Vol. 2 Issue 8, p17 

    Announces that Allos Therapeutics has published results from a clinical study conducted by researchers at the Memorial Sloan-Kettering Cancer Center on PDX as treatment for non-small cell lung cancer. Response rate and symptomatic benefit from the drug.

  • Cancer News Round-up.  // PharmaWatch: Monthly Review;September 2004, Vol. 3 Issue 9, p4 

    Reports on news and developments concerning pharmaceutical companies focusing on cancer treatment. Bioenvision's trials of breast cancer drug; Orphan drug status awarded to Allos Therapeutics breast cancer drug; U.S. Food and Drug Administration's (FDA) recommendation for wider use of Eli...

  • Spectrum Pharmaceuticals Agrees to Acquire Allos Therapeutics After Apaziquone Setback. Cartwright, Heather // PharmaDeals Review;2012, Vol. 2012 Issue 4, p55 

    Spectrum Pharmaceuticals has agreed to buy the cancer drug developer Allos Therapeutics for US$1.82 per share in cash, which represents a 27% premium over Allos' closing price prior to the announcement of the transaction. Allos shareholders will also receive a contingent value right that...

  • Allos new drug application to be reviewed by FDA panel.  // PharmaWatch: Cancer;May 2004, Vol. 3 Issue 5, p7 

    Reports on Allos Therapeutics' disclosure that the oncologic drugs advisory committee of the U.S. Food and Drug Administration plans to review the company's investigational radiation sensitizer, RSR13, on May 3, 2004. Mechanism of action of the drug; Agency's acceptance of the company's new drug...

  • Allos Therapeutics to Present at Upcoming Investor Conferences.  // Biomedical Market Newsletter;4/30/2011, p5 

    The article announces that members of the senior management of Allos Therapeutics Inc. will present at several conferences including Needham Healthcare Conference and Leerink Swann Cancer Roundtable Conference in the U.S. It mentions that the firm is committed to the development and...

  • Onyx Raises $185 Million On Nexavar Data In Liver Cancer. Morrison, Trista // BioWorld Today;6/22/2007, Vol. 18 Issue 121, p1 

    The article reports that Onyx Pharmaceuticals Inc. is raising $185 million in response to the positive prospects of its kidney cancer drug Nexavar. Onyx will be offering 6.6 million shares at $28 per share in a transaction managed and underwritten by Morgan Stanley & Co. Inc. and Merrill Lynch &...

  • Cancer News Round-up.  // PharmaWatch: Monthly Review;Sep2006, Vol. 5 Issue 9, p4 

    The article reports developments in the pharmaceutical industry worldwide from July 15, 2005 to August 14, 2006. The drugs for the treatment of kidney cancer and renal cell carcinoma from Pfizer Inc. and Bayer AG and Onyx Pharmaceuticals Inc. have gained approval to be sold in Europe. Pfizer's...

  • Onyx's Shares Plummeted on NSCLC Data.  // Bioworld Week;2/25/2008, Vol. 16 Issue 8, p2 

    The article reports on the 26.4% drop of shares of Emeryville, California-based Onyx Pharmaceuticals Inc. due to the termination of the Phase III study of Nexavar, a non-small-cell lung cancer drug. It notes that the termination of the trial is associated with the lack of efficacy of the...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics